Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Scientists from Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have discovered new GTPase KRAS and/or GTPase KRAS (mutant) inhibitors that are potentially useful for the treatment of cancer, autoimmune disorders and inflammation.
Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Sunrise Oncology (Hong Kong) Ltd. has disclosed GTPase KRAS inhibitors in a recent patent. They are described as potentially useful for the treatment of cancer.
Alterome Therapeutics Inc. has divulged substituted pyrido[4,3-d]pyrimidines acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Shenzhen Forward Pharmaceutical Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS G12C, G12D and G12V mutant inhibitors reported to be useful for the treatment of pancreatic cancer.
Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Université de Montréal has disclosed GTPase KRAS G12D mutant inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and immunological disorders.
